Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-04-10
2004-02-03
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S085000, C546S086000, C546S087000
Reexamination Certificate
active
06686372
ABSTRACT:
FIELD OF INVENTION
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;
3
adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
BACKGROUND OF THE INVENTION
The current preferred treatment for Type II, non-insulin dependent diabetes as well as obesity is diet and exercise, with a view toward weight reduction and improved insulin sensitivity. Patient compliance, however, is usually poor. There are no currently approved medications that adequately treat either Type II diabetes or obesity. The invention described herein is directed toward an effective and timely treatment for these serious diseases.
One therapeutic opportunity that has been recently recognized involves the relationship between adrenergic receptor stimulation, anti-hyperglycemic effects, and metabolic events such as increased basil metabolic rate. Compounds that act as &bgr;
3
adrenergic receptor agonists have been shown to exhibit a marked effect on lipolysis, thermogenesis, and serum glucose levels in animal models of Type II (non-insulin dependent) diabetes.
The &bgr;
3
receptor, which is found in several types of human tissue including human fat tissue, has roughly 50% homology to the &bgr;
1
and &bgr;
02
receptor subtypes yet is considerably less abundant. The importance of the &bgr;
3
receptor is a relatively recent discovery since the amino-acid sequence of the human receptor was only elucidated in the late 1980's. A large number of publications have appeared in recent years reporting success in discovery of agents that stimulate the &bgr;
3
receptor. Despite these recent developments there remains a need to develop a selective &bgr;
3
receptor agonist which has minimal agonist activity against the &bgr;
1
and &bgr;
2
receptors.
The present invention provides methods of treating Type II diabetes, treating obesity, and stimulating the &bgr;
3
receptor. In addition, the present invention also provides novel compounds that are selective &bgr;
3
receptor agonists and as such are useful for treating Type II diabetes, obesity, and stimulating the &bgr;
3
receptor. U.S. Pat. No. 4,503,067 discloses carbazolyl-(4)-oxypropanolamine compounds, some of which are within the scope of formula I, as &bgr;-adrenoceptor antagonists and vasodilators.
SUMMARY OF INVENTION
The present invention provides methods of treating Type II diabetes, treating obesity, and stimulating the &bgr;
3
receptor which comprise administering to a patient in need thereof a compound described in Formula I below.
wherein:
X
1
is —OCH
2
—, —SCH
2
—, or a bond;
X
2
is a bond, or a 1 to 5 carbon straight or branched alkylene;
X
3
is O, S, or a bond;
R
1
is a fused heterocycle of the formula:
the A
1
groups are independently carbon or nitrogen, provided that no more than 2 nitrogens may be contained in either fused 6 membered ring and those 2 nitrogens may not be adjacent;
R
2
is independently hydrogen, C
1
-C
4
alkyl, or aryl;
R
3
is hydrogen or C
1
-C
4
alkyl;
R
4
is an optionally substituted heterocycle or a moiety selected from the group consisting of:
R
5
is hydrogen or C
1
-C
4
alkyl;
R
6
is hydrogen, C
1
-C
4
alkyl, or CO
2
(C
1
-C
4
alkyl);
or R
5
and R
6
combine with the carbon to which each is attached to form a C
3
-C
6
cycloalkyl;
or R
6
combines with X
2
and the carbon to which each is attached to form a C
3
-C
8
cycloalkyl;
or R
6
combines with X
2
, R
4
, and the carbon to which each is attached to form:
provided that R
5
is hydrogen;
R
7
is independently hydrogen, halo, hydroxy, OR
2
, C
1
-C
4
alkyl, C
1
-C
4
haloalkyl, aryl, COOR
2
, CONR
2
R
2
, NHCOR
2
,
R
9
is hydrogen, halo, hydroxy, CN, OR
10
, C
1
-C
4
alkyl, C
1
-C
4
haloalkyl, CO
2
R
2
, CONR
11
R
12
, CONH(C
1
-C
4
alkyl or C
1
-C
4
alkoxy), SR
2
, CSNR
2
, CSNR
11
R
12
, NR
2
SO
2
R
2
, SO
2
R
2
, SO
2
NR
11
R
12
, SOR
2
, NR
11
R
12
, optionally substituted aryl, optionally substituted heterocycle, or C
2
-C
4
alkenyl substituted with CN, CO
2
R
2
or CONR
11
R
12
;
R
10
is C
2
-C
4
alkyl, C
1
-C
4
haloalkyl, (CH
2
)
n
C
3
-C
8
cycloalkyl, (CH
2
)
n
aryl, (CH
2
)
n
heterocycle, (CH
2
)
n
C
3
-C
8
optionally substituted cycloalkyl, (CH
2
)
n
optionally substituted aryl, (CH
2
)
n
optionally substituted heterocycle, or (CH
2
)
n
CO
2
R
2
;
R
11
and R
12
are independently hydrogen, C
1
-C
4
alkyl, aryl, (CH
2
)
n
aryl, or combine with the nitrogen to which each is bound to form morpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl;
m is 0 or 1; and
n is independently 0, 1, 2, or 3; or a pharmaceutically acceptable salt thereof.
Another embodiment of the present invention is the genus of novel compounds defined by Formula II below.
wherein:
X
1
is —OCH
2
—, —SCH
2
—, or a bond;
X
3
is O, S, or a bond;
R
1
is a fused heterocycle of the formula:
the A
1
groups of said heterocycle are independently carbon or nitrogen, provided that no more than 2 nitrogens may be contained in either fused 6 membered ring and those 2 nitrogens may not be adjacent;
R
2
is independently hydrogen, C
1
-C
4
alkyl, or aryl;
R
3
is hydrogen or C
1
-C
4
alkyl;
R
4
is an optionally substituted heterocycle or a moiety selected from the group consisting of:
X
2
is a bond, or a 1 to 5 carbon straight or branched alkylene;
R
5
is hydrogen or C
1
-C
4
alkyl;
R
6
is hydrogen, C
1
-C
4
alkyl, or CO
2
(C
1
-C
4
alkyl);
or R
5
and R
6
combine with the carbon to which each is attached to form a C
3
-C
6
cycloalkyl;
or R
6
combines with X
2
and the carbon to which each is attached to form a C
3
-C
8
cycloalkyl;
or R
6
combines with X
2
, R
4
, and the carbon to which each is attached to form:
provided that R
5
is hydrogen;
R
7
is independently hydrogen, halo, hydroxy, OR
2
, C
1
-C
4
alkyl, C
1
-C
4
haloalkyl, aryl, COOR
2
, CONHR
2
, NHCOR
2
, C
1
-C
4
alkoxy, NHR
2
, SR
2
, CN, SO
2
R
2
, SO
2
NHR
2
, or SOR
2
;
R
8
is independently hydrogen, halo or C
1
-C
4
alkyl;
R
9
is halo, CN, OR
10
, C
1
-C
4
alkyl, C
1
-C
4
haloalkyl, CO
2
R
2
, CONR
11
R
12
, CONH(C
1
-C
4
alkyl or C
1
-C
4
alkoxy), SR
2
, CSNR
2
, CSNR
11
R
12
, NR
2
SO
2
R
2
, SO
2
R
2
, SO
2
NR
11
R
12
, SOR
2
, NR
11
R
12
, optionally substituted aryl, optionally substituted heterocycle, or C
2
-C
4
alkenyl substituted with CN, CO
2
R
2
or CONR
11
R
12
;
R
10
is C
1
-C
4
alkyl, C
1
-C
4
haloalkyl, (CH
2
)
n
C
3
-C
8
cycloalkyl, (CH
2
)
n
aryl, (CH
2
)
n
heterocycle, (CH
2
)
n
C
3
-C
8
optionally substituted cycloalkyl, (CH
2
)
n
optionally substituted aryl, (CH
2
)
n
optionally substituted heterocycle, or (CH
2
)
n
CO
2
R
2
;
R
11
and R
12
are independently hydrogen, C
1
-C
4
alkyl, aryl, (CH
2
)
n
aryl, or combine with the nitrogen to which each is bound to form morpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl;
m is 0 or 1;
n is independently 0, 1, 2, or 3; provided:
when R
5
or R
6
is hydrogen; either
1) one or more A
1
must be nitrogen, or
2) R
9
is CN, OR
10
, CO
2
R
2
, CSNR
2
, CSNR
11
R
12
, NR
2
SO
2
R
2
, SO
2
NR
11
R
12
, optionally substituted aryl, optionally substituted heterocycle, or C
2
-C
4
alkenyl substituted with CN, CO
2
R
2
or CONR
11
R
12
; and
R
10
is C
1
-C
4
haloalkyl, (CH
2
)
n
C
3
-C
8
cycloalkyl, (CH
2
)
n
heterocycle, (CH
2
)
n
C
3
-C
8
optionally substituted cycloalkyl, (CH
2
)
n
optionally substituted aryl, or (CH
2
)
n
optionally substituted heterocycle; or a pharmaceutically acceptable salt thereof.
The present invention also provides novel processes for making, as well as novel pharmaceutical formulations of the compounds of Formula II.
The compounds of Formula I are selective &bgr;
3
receptor agonists and as such are useful for treating Type II diabetes and obesity, as well as useful for stimulating or activating the &bgr;
3
receptor. Therefore, the present invention also provides for methods of treating Type II diabetes and obesity, as well as a method of stimulating or activating the &bgr;
3
receptor.
In additi
Crowell Thomas A.
Evrard Deborah A.
Jones Charles D.
Muehl Brian S.
Rito Christopher J.
Eli Lilly and Company
Morris Patricia L.
Skelton Jeffrey J.
Voy Gilbert T.
LandOfFree
Selective &bgr;3 adrenergic agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective &bgr;3 adrenergic agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective &bgr;3 adrenergic agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3309964